Pharmagen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHRX research report →
Price Chart
About the company
Pharmagen, Inc. , a pharmaceutical company located in Silver Spring, Maryland, operates primarily as a distributor within the U. S.
- CEO
- Mackie A. Barch
- IPO
- 2012
- Employees
- 24
- HQ
- Silver Spring, MD, US
Get TickerSpark's AI analysis on PHRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.17K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 1.07
- P/B
- -0.00
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
- Gross Margin
- 63.27%
- Op Margin
- -44.86%
- Net Margin
- -134.17%
- ROE
- 85.12%
- ROIC
- 73.04%
Latest fiscal year · YoY change
- Revenue
- $4.81K+0.0%
- Gross Profit
- $3.05K+0.0%
- Op Income
- $-2,159.028
- Net Income
- $-6,457.614+0.0%
- EPS
- $-0.02+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.32
- RSI (14)
- 53
- Avg Volume
- 11.92K
No earnings-call transcripts are available for PHRX yet.
- Free Float
- 66.3%
- Shares Outstanding
- 517.08M
- Float Shares
- 343.08M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 14 | Wolpow Richard | other | 0 |
| Jun 17, 14 | Perry Stephen M. | other | 11,100,000 |
| Jun 30, 14 | Rowley David | other | 0 |
| Jun 30, 14 | SKIBSTED RUSSELL | other | 0 |
| Jun 30, 14 | Relac Boyd P. | other | 0 |
| Jun 30, 14 | Barnes Danny | other | 0 |
| Jun 30, 14 | Perry Stephen M. | other | 0 |
| Jun 17, 14 | Perry Stephen M. | buy | 11,100,000 |
| Jun 9, 14 | SKIBSTED RUSSELL | other | 0 |
| Jun 1, 14 | Rowley David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PHRX coverage
Recent articles, reports, and earnings notes.
No research on PHRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHRX report →PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
newsfilecorp.com · May 13
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
newsfilecorp.com · Jan 5
PharmaDrug Announces Debt Restructuring
newsfilecorp.com · Oct 31
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
newsfilecorp.com · Oct 30
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
newsfilecorp.com · Jul 30
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
newsfilecorp.com · Jul 30
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
newsfilecorp.com · Jun 16
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
newsfilecorp.com · Jun 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.